Skip to main content

Dr. Timothy G. Larson, M.D.

Hematology & Oncology (Hematology & Oncology Physician)

  • Medicare participating

At a glance

Years since graduation
37
In the NPI registry since
2006
Medicare patients seen, 2024
69

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 1989Medical school: University of California, San Francisco School of Medicine
  • 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Hematology & Oncology Physician primary
    MN license 38013

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Hematology & Oncology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
69
Services billed
3,316
Patients’ average age
72
Most frequent Medicare services, 2023
ServiceTimesPatients
Injection, aprepitant, 1 mg6,24025
Injection, dexamethasone sodium phosphate, 1 mg1,08038
Injection, palonosetron hcl, 25 mcg67030
Injection, leucovorin calcium, per 50 mg54011
Injection, granisetron hydrochloride, 100 mcg50018
Injection, fluorouracil, 500 mg34611
Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count30485
Injection of additional new drug or substance into vein30455
Insertion of needle into vein for collection of blood sample22580
Blood test, comprehensive group of blood chemicals18069

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 3 companies reported 5 payments worth $8,904 in total to this clinician.

By company
Genentech USA, Inc.$8,661
Genentech, Inc.$164
Tempus Ai, Inc$79.10
By type
Consulting Fee$8,025
Travel and Lodging$491
Food and Beverage$388

What the payments were for

Largest payments other than meals
DateCompanyWhat it was forAmount
Oct 22, 2025Genentech USA, Inc.
Oct 22, 2025
Consulting Fee$8,025
Oct 22, 2025Genentech USA, Inc.
Oct 22, 2025
Travel and Lodging
travel to St. Louis, MO · in-kind
$491

Each payment as the company reported it, with the products it named. Meals are counted in the totals above but not listed one by one.

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in Minnesota →

Industry-funded research

Named as a principal investigator on 7 industry-funded studies in 2025, from 5 companies. The companies reported $819,296 in research payments for these studies, mostly to the institutions running them.

  • A Phase 2, Open-label, Randomized, Multicenter Study of Tarlatamab Dosing Regimens in Subjects With Small Cell Lung Cancer (SCLC) (DeLLphi-309)
    Amgen Inc.
  • A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
    Daiichi Sankyo Inc. · Recruiting · NCT06172478
  • A Phase 1b Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Mas…
    Amgen Inc.
  • A Phase III, Double-blind, Placebo-controlled, Multi-center International Study of Neoadjuvant/adjuvant Durvalumab for the Treatment of Patients with Resectable Stages II and III Non-small Cell Lung Cancer
    AstraZeneca Pharmaceuticals LP
  • A Phase 1/2 Study Evaluating the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Efficacy of AMG 193 in Combination With IDE397 in Subjects With Advanced MTAP-null Solid Tumors
    Amgen Inc.
  • An Open Label Investigational Immuno-therapy Trial of Nivolumab in Cancers That Are Advanced or Have Spread
    E.r. Squibb & Sons, L.l.c. · Completed · NCT02832167
  • Single-arm, open label, phase II study of MBG453 (sabatolimab) added to FDA approved Hypomethylating agents of investigator's choice (IV/SC/Oral) for patients with intermediate, high or very high risk myelodysplastic …
    Novartis Pharmaceuticals Corporation

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Other Hematology & Oncology clinicians in Minneapolis

Sources

NPI registry (CMS NPPES, November 2026; record last updated October 27, 2011), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1326130204. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.